Clinical trials: Unresectable Melanoma
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Locally Advanced Basal Cell Carcinoma
A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)
This study will test an experimental Regeneron drug called cemiplimab ("study drug") given alone or in combination with other anti-cancer drugs ("combination treatment") to see if they can help treat laBCC.
- Trial name
- NCT07808515
- Testing
- Cemiplimab, Vidutolimod, Fianlimab
- Volunteers
- 135 people
- Sponsor
- Regeneron Pharmaceuticals
Melanoma
Biochemotherapy With Temozolomide for Metastatic Melanoma
The goal of this clinical research study is to learn if treatment with Temodar (temozolomide), Velban (vinblastine), Cisplatin, Proleukin (interleukin-2), Intron-A (interferon alpha), and thalidomide can help to control melanoma…
- Trial name
- NCT00505635
- Testing
- Temozolomide, Velban, Cisplatin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Melanoma
A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma
This study will assess the preliminary anti-tumor activity and safety profile of a combination of bevacizumab and dacarbazine in participants with unresectable/metastatic melanoma not previously treated with chemotherapy for…
- Trial name
- NCT01164007
- Testing
- Bevacizumab, Dacarbazine
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced Melanoma
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced…
- Trial name
- NCT07223411
- Testing
- Fianlimab + Cemiplimab, Relatlimab + Nivolumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- John Kirkwood
Melanoma, Skin Cancer
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
The purpose of this study is to see if BMS-986205 combined with nivolumab, compared to nivolumab by itself, is more effective in treating Melanoma that has spread or is unable to be removed by surgery, and has not previously been…
- Trial name
- NCT03329846
- Testing
- BMS-986205, Nivolumab
- Where
- 63 sites in United States, Australia and 14 more
- Volunteers
- 20 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Melanoma
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
This research study is studying a combination of drugs as a possible treatment for unresectable or metastatic melanoma. The drugs involved in this study are: Pembrolizumab (Keytruda) Trametinib (Mekinist) Dabrafenib (Tafinlar)
- Trial name
- NCT03149029
- Testing
- Pembrolizumab, Dabrafenib, Trametinib
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Melanoma
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma
This is an adaptive clinical trial that includes a dose escalation phase followed by a randomized controlled Phase 3 trial. The purpose of the dose escalation phase is to establish the Phase 3 dose of indoximod in combination…
- Trial name
- NLG2107 (NCT03301636)
- Testing
- Pembrolizumab, Nivolumab, Indoximod
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- NewLink Genetics Corporation
Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
This phase Ib/II trial studies the side effects and best dose of CMP-001 and how well it works when given together with INCAGN01949 in treating patients with stage IV pancreatic cancer and other cancers except melanoma.
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04387071
- Testing
- Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of Southern California
Melanoma
Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma
This is a patient oriented translational research project aiming to improve clinical outcomes for patients with BRAF and NRAS wild-type unresectable Stage III or Stage IV metastatic melanoma who have progressed on, or are unable…
- Trial name
- Match Mel (NCT02645149)
- Testing
- Standard therapy or clinical trial, Matched targeted therapy, Trametinib and / or supportive care
- Where
- 2 sites in Australia
- Volunteers
- 216 people
- Sponsor
- Melanoma Institute Australia
Recurrent Metastatic Melanoma, Cutaneous Melanoma
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
The purpose of this study is to evaluate how effective Olaparib is when given as a treatment for primary or recurrent, unresectable or metastatic melanoma. This research study involves targeted therapy.
- Conditions
- Recurrent Metastatic Melanoma, Cutaneous Melanoma, Mucosal Melanoma, Uveal Melanoma
- Trial name
- NCT05482074
- Testing
- Olaparib
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, Metastatic Malignant Solid Neoplasm
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
This phase I trial studies the best dose and side effects of trigriluzole in combination with nivolumab and pembrolizumab in treating patients with solid malignancies or lymphoma that has spread to other places in the body or…
- Conditions
- Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer
- Trial name
- NCT03229278
- Testing
- Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Rutgers, The State University of New Jersey
Melanoma
Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma
This phase I/II trial studies the safety, best dose and effectiveness of targeted gene therapy combined with isolated limb infusion (ILI) of melphalan and dactinomycin for treating patients with advanced extremity melanoma that…
- Trial name
- NCT01531244
- Testing
- dactinomycin, melphalan, Conditionally replicative adenovirus 3/5-delta
- Sponsor
- Washington University School of Medicine
Advanced Cancers
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
The goal of this clinical research study is to find the highest tolerable doses of the combinations of lenalidomide and other drugs that can be given to patients with advanced cancer.
- Trial name
- NCT01183663
- Testing
- Lenalidomide, Bevacizumab, Sorafenib
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
Intraocular Melanoma, Melanoma (Skin)
Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide and lomustine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00072345
- Testing
- lomustine, temozolomide, thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Melanoma
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or…
- Trial name
- coBRIM (NCT01689519)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 156 sites in United States, Australia and 17 more
- Volunteers
- 495 people
- Sponsor
- Hoffmann-La Roche
Malignant Melanoma
Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma
This is an open-label, multi-center, clinical phase II study to explore the correlation of the genetic make-up of the treated tumor before start of therapy and to correlate clinical response at 8 weeks as well as metabolic…
- Trial name
- BOTTOM (NCT02410863)
- Testing
- Dabrafenib, Trametinib
- Where
- 6 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Prof. Dr. med. Dirk Schadendorf
Melanoma
International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma
An International Multicenter Open-label Randomized Trial of the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) as Monotherapy in Patients with Unresectable/Metastatic Melanoma.
- Trial name
- MIRACULUM (NCT03269565)
- Testing
- BCD-100
- Where
- 9 sites in Russia
- Volunteers
- 126 people
- Sponsor
- Biocad
Unresectable or Metastatic Melanoma
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone.
- Trial name
- NCT01844505
- Testing
- Nivolumab, Ipilimumab
- Where
- 150 sites in United States, Australia and 20 more
- Volunteers
- 945 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Melanoma
A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients
Thi pahse I, dose-escalation trial will determine the MTD, safety and the additional benefit achieved from adding SGI-110 to ipilimumab therapy in metastatic melanoma patients.
- Trial name
- NIBIT-M4 (NCT02608437)
- Testing
- SGI-110, Ipilimumab
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- Italian Network for Tumor Biotherapy Foundation